Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.

Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell PH, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, Defazio A, Chenevix-Trench G, Australian Ovarian Cancer Study Group, Dolan ME
Clin Cancer Res. 2011 17 (16): 5490-500

PMID: 21705454 · PMCID: PMC3160494 · DOI:10.1158/1078-0432.CCR-11-0724

MeSH Terms (15)

Antineoplastic Agents Carboplatin Cell Line Cell Line, Tumor Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Genome, Human Genome-Wide Association Study Humans Kaplan-Meier Estimate Ovarian Neoplasms Polymorphism, Single Nucleotide Prognosis Treatment Outcome

Connections (2)

This publication is referenced by other Labnodes entities: